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A new reverse transcription–polymerase chain reac-
tion assay was developed for identification of 28 Canadian
human parechovirus (HPeV) isolates, including 20 HPeV-1,
3 HPeV-2, and 5 HPeV-3, recovered from 1985 to 2004. All
HPeV-1 isolates but 1 were genetically distinct from the
Harris reference strain. One HPeV-2 isolate was related to
the Williamson strain; the other 2 were related to the
Connecticut strain. HPeV-3 isolates clustered together.
Seventy-five percent of isolates were recovered during the
typical enterovirus season. All patients but 1 were children
with a mean age of 14.6 months, 6.3 months, and 0.7
months for HPeV-1, HPeV-2, and HPeV-3 patients, respec-
tively. All HPeV-2– and HPeV-3–infected children were hos-
pitalized with a diagnosis of viremia or sepsis. HPeV-1–
infected children had bronchiolitis diagnosed in 50% of the
cases, with few cases of pneumonia and enteritis. Two
infected patients (1 child with leukemia and a 78-year-old
woman) died of septic shock and severe pneumonia,
respectively.
P
icornaviruses constitute a diverse family of single-
stranded positive-sense RNA viruses whose genome is
packed into a nonenveloped icosahedral capsid (1). Within
the Picornaviridae family, 5 genera are known to cause
infections in humans: Enterovirus, Hepatovirus,
Rhinovirus,  Kobuvirus, and Parechovirus (1). The
Parechovirus genus contains 3 human pathogens (HPeV-1,
-2, and -3) as well as Ljungan virus, a rodent parechovirus
isolated from bank voles (2). These viruses have several
atypical biologic and molecular properties compared to
other picornaviruses, such as unusual cytopathic effects
and the lack of cleavage of the VP0 protein into VP4 and
VP2, which results in a virion particle with only 3 capsid
proteins rather than 4 (3).
Previous studies demonstrated that HPeV-1 (formerly
echovirus 22) had a worldwide distribution and was asso-
ciated with diseases similar to those caused by human
enteroviruses (HEVs), i.e., gastroenteritis, respiratory dis-
eases, aseptic meningitis, encephalitis, and neonatal sep-
sis–like syndromes (3–6). In general, HPeV-1 seems to be
responsible for more gastrointestinal and respiratory syn-
dromes and for fewer central nervous system (CNS) symp-
toms than enteroviruses (3,6). HPeV-2 (formerly echovirus
23) has been rarely reported, despite its early description in
1961 (7). In a retrospective Swedish study covering a peri-
od of >30 years, only 5 cases of HPeV-2 infections (includ-
ing 4 cases of gastrointestinal symptoms and 1 case of
respiratory symptoms) were reported (8), compared to 109
HPeV-1 infections during the same period (9). The third
type of HPeV (HPeV-3) was reported in 2004 from stool
specimen of a 1-year-old Japanese girl with transient paral-
ysis (10). Subsequently, we reported 3 cases of sepsislike
illnesses attributable to HPeV-3 infections in Canadian
neonates (11). The association of HPeV-3 with 3 cases of
sudden infant death syndrome was also suggested (12). In
a recent Dutch study, HPeV-3 was shown to be more
involved in CNS infections than HPeV-1 (13).
Similar to HEVs, HPeVs infections are commonly
identified by virus isolation in cell culture, followed by
neutralization typing (6,9). Isolation in cell culture is labo-
rious and time-consuming. In addition, the method may
lack sensitivity, thus leading to false-negative results
(14,15). Because of increasing knowledge of genome
sequences of HPeVs, development of molecular tech-
niques such as reverse transcription–polymerase chain
reaction (RT-PCR) could be an important alternative tool
for specific and sensitive detection of these viruses. The
increased sensitivity of RT-PCR compared to virus isola-
tion has already been demonstrated for other clinically
important picornaviruses such as enteroviruses and rhi-
noviruses (16–19). Nevertheless, HPeVs could not be
detected by most molecular assays designed for HEV diag-
nosis because of considerable sequence differences
between these 2 viral genera (20–22). In this study, we
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Canada developed a single RT-PCR test for detecting the 3 HPeV
types based on sequence alignments of HPeV-1, -2, and -3
reference strains and various clinical HPeV isolates. This
test was applied for the identification of several putative
HPeV isolates recovered in Quebec (Canada) during the
last 2 decades (1985–2004). 
Materials and Methods 
Viral Strains and Cell Culture Procedures
A total of 30 HPeV strains, including the reference
strains Harris (HPeV-1, ATCC VR-52), and Williamson
(HPeV-2, ATCC VR-53), as well as 28 clinical HPeV iso-
lates were used in this study (Table). Clinical specimens of
various origins, such as nasopharyngeal aspirates (NPA),
throat swabs, stools, cerebrospinal fluid (CSF), and endo-
tracheal secretions (online Appendix Table, available from
http://www.cdc.gov/ncidod/EID/vol12no06/05-1675.htm#
table_app), were first added to different continuous cell
lines, including human lung adenocarcinoma (A-549),
human rhabdosarcoma (RD), transformed human kidney
(293), human colon adenocarcinoma (HT-29), human
laryngeal carcinoma (Hep-2), human foreskin fibroblast,
mink lung, African green monkey kidney (Vero), Madin
Darby canine kidney , and rhesus monkey kidney (LLC-
MK2) cells. The viral cultures were incubated for 3 weeks
at 37°C in a 5% CO2 atmosphere. Viral isolates with cyto-
pathic effects (CPE) suggestive of HEV or HPeV were fur-
ther analyzed by neutralization assays with Lim and
Benyesh-Melnick antiserum pools A-H (National Institutes
of Health, Bethesda, MD, USA) and specific antisera for
HPeV-1 and -2 (MABioproducts, Walkersville, MD, USA). 
Molecular Characterization
HPeV genomic RNAwas isolated from the supernatant
of infected cell cultures with the QIAamp Viral RNA kit
(Qiagen, Mississauga, Ontario, Canada). cDNA was pre-
pared by using the HPeVUniv5′ primer selected from the
C-terminal region of the capsid VP0 encoding gene: 5′-
GCT GAC CTA TGY ATC CCC TAT GT-3′ (nt
1358–1379, GenBank accession no. AJ998818) and the
SuperScript II reverse transcriptase (Gibco BRL,
Burlington, Ontario, Canada). Viral cDNAwas then ampli-
fied by PCR by using the Pfu Turbo Polymerase
(Stratagene, La Jolla, CA, USA) and primers HPeVUniv5′
and HPeVUniv3′ (selected from the N-terminal region of
the capsid VP1 encoding gene): 5′-GTG AAC CCC AYG
AAT TTT GGA A-3′ (nt 2351–2330, accession no.
AJ998818). After a primary denaturation step at 95°C for
5 min, 35 cycles of denaturation at 94°C for 50 s, anneal-
ing at 58°C for 50 s, and extension at 72°C for 2 min were
performed, followed by a final extension step at 72°C for
7 min. PCR products were analyzed by electrophoresis on
a 1.2 % agarose gel and the expected amplicons of ≈1,000
bp were purified by using the GenElute PCR clean-up kit
(Sigma-Aldrich, St-Louis, MO, USA). Nucleotide
sequences of PCR products were determined with PCR
primers by using an automated DNA sequencer (ABI
Prism 377A; Perkin-Elmer Applied Biosystems, Foster
City, CA, USA). The nucleotide sequences were analyzed,
and the deduced amino acid sequences were aligned by
using ClustalW (available from http://www.infobiogen.
fr/). The resulted alignment was analyzed by the neighbor-
joining method with the MEGA2 (Biodesign Institute,
Arizona State University, Phoenix, AZ, USA) program for
the construction of the phylogenetic tree.
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Demographic and clinical informations were retrospec-
tively collected from clinical charts of hospitalized
patients for whom a positive culture for HPeV was
obtained in our laboratory in the past 20 years. The Mann-
Whitney rank sum test was used to compare the mean age
of patients infected with HPeV-1 versus HPeV-3; the
Fisher exact test was used to compare HPeV-1 versus the 2
other HPeV types regarding the rate of underlying diseases
and the nature of initial diagnosis.
Results
Virologic and Molecular Findings
Among the different cell lines used, HT-29 was found
to be the most suitable for efficient isolation of HPeV-1
and -2. Both grew efficiently in this cell line with an evi-
dent CPE noted after a mean incubation time of 3.8 days
(range 1–8 days). A presumptive distinction between
HPeV- and HEV-induced CPE in this cell line was possi-
ble. Parechovirus-infected cells were large, regularly
shaped spheres, whereas enterovirus-infected cells were
rather small with an irregular shape (Figure 1A). On the
other hand, HPeV-3 isolates only initially grew on LLC-
MK2 cells after a mean incubation time of 16 days (range
14–17 days). On passage, however, these viruses grew rap-
idly (in ≈1–3 days) in the same cell line (Figure 1B) and in
Vero cells. All tested HPeV-1 and only one third of HPeV-
2 (Can82047-01) isolates were neutralized by specific
antisera for HPEV-1 and -2 (Table). 
All HPeV clinical isolates as well as the 2 HPeV-1 and
-2 reference strains were efficiently amplified by our RT-
PCR test, generating an amplicon of the expected size
(≈1,000 bp). No PCR products were generated from
enterovirus (coxsackievirus A4 and coxsackievirus B4)
and rhinovirus (n = 2) clinical isolates. Conversely, our
HPeV isolates were negative when tested by our HEV RT-
PCR assay, which is based on the amplification of the 5′
noncoding region. Sequencing of HPeV PCR products
confirmed the presence of the VP3 gene in our HPeV-1 (n
= 20), HPeV-2 (n = 3) and HPeV-3 (n = 5) clinical isolates.
Sequence analysis showed that HPeV-1 clinical isolates
had 75.0% to 85.1% nt and 89.2 to 97.5% amino acid iden-
tities with the prototype Harris strain (accession no.
S45208) (Table). HPeV-2 isolates had nucleotide and
amino acid identities of 67.8% to 81.1% and 72.5% to
96.4%, respectively, with the prototype Williamson strain
(accession no. AJ005695). Of note, Can95219-03 and
Can95224-03 HPeV-2 isolates had the same sequence and
were more related to the Connecticut CT-80-6760 HPeV-2
strain (accession no. AF055846) with which they had
nucleotide and amino acid identities of 85.1% and 95.8%,
respectively. HPeV-3 isolates had nucleotide and amino
acid identities of 95.0% to 95.5% and 95.7% to 96.4%,
respectively, with the Japanese A308/99 HPeV-3 isolate
(accession no. AB084913).
Phylogenetic analysis confirmed the identities of HPeV
isolates. The HPeV-1 isolate Can81805-01 was closely
related to the reference Harris strain (lineage II), whereas
the remaining 19 isolates from this study, as well as 3 other
Japanese HPeV-1 isolates (A1087-99, A942-99, and
A10987-00), were found to form a distinct cluster (lineage
I) (Figure 2). The HPeV-2 isolate Can82047-01 was relat-
ed to the reference Williamson strain (lineage I), whereas
the other 2 HPeV-2 isolates, Can95219-01 and Can95224-
01 HPeV-2, were somewhat related to the Connecticut
CT80-6760 strain (lineage II). Finally, all HPeV-3 isolates
formed a separate cluster that also included other Japanese
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Figure 1. Cytopathic effects (CPEs)
observed 3 days after infection of HT-29
cells with an enterovirus or a human
parechovirus (HPeV)-1 isolate after 1
passage on this cell line (A); CPE
observed 1 day after infection of LLC-
MK2 cells with a HPeV-3 isolate after 3
passages on this cell line (B).HPeV-3 isolates (A308-99, A628-99, A317-99, and A354-
99).
The alignment of the predicted amino acid sequences of
the partial VP0–VP3 region of Canadian HPeV-1, -2 and
-3 isolates with the reference strains showed differences in
the VP0/VP3 cleavage site, which was N/N in Can952219-
03 and Can95224-03 (HPeV-2), N/S in Connecticut CT80-
6760, T/Ain Williamson and Can82047-01 (HPeV-2), N/A
in Harris and all Canadian HPeV-1 isolates, and N/G in all
HPeV-3 isolates (Figure 3). The length of the N-terminal
extension of the VP3 protein, which is a molecular feature
of parechoviruses, was also shown to differ from 27
residues in HPeV-1 of lineage I to 34 residues in HPeV-2
of lineage II. HPeV-1 of lineage II and HPeV-2 of lineage
I had an extension of 28 residues, whereas an extension of
30 residues was seen in all HPeV-3 isolates (Figure 3).
Clinical Manifestations of HPeV Infections 
Twenty-eight HPeV isolates, recovered in the Quebec
City area between 1985 and 2004, were available for this
study (Table). This collection included 20 (71.4%) HPeV-
1, 3 (10.7%) HPeV-2, and 5 (17.8%) HPeV-3. The viral
isolates were recovered predominantly from NPAs (n =
16), but also from throat swab specimens (n = 2), endotra-
cheal secretions (n = 2), stool samples (n = 7), and CSF (n
= 1) (online Appendix Table). In addition, for 2 patients, a
second concomitant HPeV isolate was recovered from
another site (urine in patient 7 and NPA from patient 20).
Complete clinical findings were obtained for 23 (82.1%)
of the 28 patients, whereas partial information was avail-
able for the remaining 5 patients.
Twenty-seven (96.4%) of the 28 patients were children
<4 years (mean 11.1 months, median 7.0 months, range 1
week to 4 years). Mean age was 14.6, 6.3, and 0.7 months
for HPeV-1–, HPeV-2–, and HPeV-3–infected children,
respectively (p<0.001 for comparison of HPeV-1 vs HPeV-
3). The 78-year-old adult excreted HPeV-1 in her endotra-
cheal secretions. The female-to-male ratio was 1.2 (54.2%
vs. 45.8%). Seventy-five percent of all HPeV isolates were
recovered during the typical enterovirus season, i.e., dur-
ing summer (28.6%) and fall (46.4%). The epidemiology
of the newly described HPeV-3 was similar to that of other
HPeVs, with 80% of this viral serotype isolated during the
summer-fall period.
Among patients for whom information was available,
33.3% (8/24) had an underlying disease, including 2 chil-
dren with acute lymphoblastic leukemia (ALL) (online
Appendix Table). Patients with underlying diseases repre-
sented 47.0% (8/17) of those who excreted HPeV-1 com-
pared to none of the 7 HPeV-2–or HPeV-3–infected
patients (p = 0.18 for comparison of HPeV-1 vs other
HPeVs). Twenty-four (96.0%) of the 25 patients with
available information were hospitalized (mean number of
days 11.4, median 3.0, range 1–129). However, if the 3
patients with nosocomial HPeVs are excluded, the mean
duration of hospitalization was 3.7 days; this finding was
similar for the different HPeV types (mean of 3.3, 3.0, and
5.0 days for HPeV-1, -2 and -3, respectively). Only 3
(12.0%) of 25 patients were admitted to the intensive care
unit. These 3 patients were infected with HPeV-1, and 2 of
them (patients 6 and 26), a 4-year old boy with ALL and
a 78-year-old woman, died of respiratory failure. A
copathogen was found in 5 (20.8%) of 24 HPeV-infected
patients, including 3 patients with human respiratory syn-
cytial virus (HRSV), 1 with adenovirus, and 1 with human
parainfluenza virus (HPIV) type 3.
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Figure 2. Phylogenetic analysis of Canadian human parechovirus
(HPeV) isolates and HPeV-1 (Harris, GenBank accession no.
S45208), HPeV-2 (Williamson, AJ005695, and Connecticut,
AF055846), and HPeV-3 (A308-99, AB084913) reference strains
based on the ClustalW alignment of the VP3 amino acid
sequences. Japanese HPeV-1 (A1087-99, accession no.
AB112485; A942-99, AB112486; and A10987-00, AB112487) and
HPeV-3 (A628-99, accession no. AB112484; A317-99, AB112482,
and A354-99, AB112483) isolates were also included in the analy-
sis. The tree was constructed by using the neighbor-joining
method with the MEGA 2 program. Bootstrap probabilities for 550
replicas are shown at the branch nodes. Only values of 70% to
100% are indicated. Boldface indicates HPeV reference strains.Among the 24 children with available information,
bronchiolitis, pneumonitis, or both, were reported as the
final diagnosis in 50.0% of cases, whereas acute otitis
media, sinusitis, and conjunctivitis were secondary diag-
noses in 37.5%, 8.3%, and 4.2% of cases, respectively
(online Appendix Table). In addition, the final diagnosis
was reported as viremia/sepsis in 29.2% of children,
whereas enteritis, de novo convulsions, and shock were
found in 29.2%, 4.2%, and 4.2% of patients, respectively.
Final diagnosis was unknown for 3 (11.1%) of 27 children
(all 3 had positive stool viral cultures). All children (7/7)
with HPeV-3 and HPeV-2 infections were admitted with a
diagnosis of viremia or sepsis, and all received broad-spec-
trum antimicrobial drugs until results of bacterial cultures
(blood, CSF, urine), whereas none (0/17) of the HPeV-1-
infected children had such an initial diagnosis (p = 0.001
for comparison of HPeV-1 vs. other HPeVs). Conversely,
bronchiolitis was found in 8 (47.0%) of 17 children with
HPeV-1 infections and in none of the patients (0/7) infect-
ed with the other 2 serotypes (p = 0.18 for comparison of
HPeV-1 vs other HPeVs). However, another viral pathogen
(HRSV or HPIV-3) was found in addition to HPeV-1 in 4
(50%) of 8 children with bronchiolitis.
A few cases are particularly worth noting. As previous-
ly mentioned, patient 6 was the only child who died after
HPeV infection in our cohort. At the time of his HPeV-1
infection, the 4-year-old boy was receiving consolidation
chemotherapy for ALL. He was admitted with high fever
(40°C), dry cough, and abdominal pain. Over a course of 4
to 5 days, the following conditions developed: bilateral
pneumonitis, which required mechanical ventilation, hep-
atitis, and septic shock complicated by renal insufficiency,
for which dialysis was necessary. He died of multiorgan
failure while receiving treatment with amphotericin B,
acyclovir, meropenem, and vancomycin; no autopsy was
performed. Apart from isolation of HPeV-1 from a throat
swab, no other microorganisms (bacteria, fungi, and virus-
es) were recovered from blood, urine, and endotracheal
secretions. Also of interest are the clinical signs and symp-
toms of 1-month-old twins infected by HPeV-2, who were
admitted to the hospital on the same day with high fever
and irritability. In 1 case (patient 20), HPeV-2 was recov-
ered from CSF and NPA samples, whereas the virus was
only isolated in NPA from the other twin (patient 21). The
viruses from the 2 children had identical VP3 gene
sequences. Both infants received broad-spectrum antimi-
crobial drugs (ampicillin plus cefotaxime) for 3 days for
suspected sepsis, and both had rapid clinical improvement.
Patient 26 was the only adult infected with HPeV (type 1)
in our study. This 78-year-old woman was admitted to the
hospital for several fractures caused by a car accident. One
month after admission, bilateral pneumonia developed.
She eventually died of respiratory failure 43 days after
admission. An endotracheal culture was positive for HPeV-
1 12 days before her death; however, results of bacterial
cultures were unavailable because part of her clinical chart
was destroyed a few years after her death in 1987. No
autopsy report was available.
Discussion
In this study, we retrospectively characterized 28 clini-
cal HPeV isolates recovered during the last 2 decades in
Québec, Canada, using a new RT-PCR assay. To date, our
study is the only one that analyzed virologic and clinical
data from the 3 HPeV serotypes. The study clearly demon-
strated the importance of these pathogens and highlighted
some clinical differences between infection caused by the
3 serotypes.
Virus isolation, followed by neutralization assays, a
procedure that has been generally used for identification of
HEVs and HPeVs, is laborious, time-consuming, and may
lack sensitivity. Because of substantial sequence differ-
ences between HEVs and HPeVs, even within the con-
served 5′ noncoding region (20–22), most molecular
techniques designed for detection of HEVs cannot detect
HPeVs (13,14). We developed a RT-PCR test for specifi-
cally detecting all 3 types of HPeV by using primers
selected from the C-terminal and N-terminal regions of
VP0 and VP1 HPeV capsid proteins, respectively. These
regions were found to be conserved in various HPeV-1, -2,
and -3 genomic sequences (data not shown). The PCR
product of ≈1,000 bp encompasses the entire VP3 gene,
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Figure 3. Comparison of the predicted partial VP0-VP3 capsid pro-
tein region of Canadian isolates with that of Harris (human pare-
chovirus [HPeV]-1), Williamson and Connecticut (HPeV-2), and
A308-99 (HPeV-3) strains. The aligned region contains 90 amino
acids corresponding to residues 244 to 334 in the Harris polypro-
tein sequence (accession no. S45208). The VP3 N-terminal exten-
sion, which is specific to parechoviruses (21), is shaded. The
cleavage site between VP0 and VP3 is underlined. Asterisks
denote conserved residues. Boldface indicates HPeV reference
strains.whose sequence differs substantially between the 3 HPeV
types, allowing their discrimination. By the use of this test,
we were able to identify HPeV-1 and -2 reference strains
as well as 28 HPeV clinical isolates, in contrast to neutral-
ization assays that failed to recognize 2 HPeV-2 isolates by
using specific HPeV-1 and -2 antisera. This molecular test
appears to be specific for HPeV since no amplifications
were found with samples of related viruses, including
enteroviruses and rhinoviruses.
By sequencing the PCR product, we could not only dif-
ferentiate the 3 HPeV types but also make an intratypic
discrimination. Our phylogenetic analysis demonstrated
the existence of 2 clusters for HPeV-1 strains. The first
contained a Can81805-01 isolate and was closely related to
the Harris reference strain; the second cluster included the
remaining 19 Canadian isolates as well as recent Japanese
HPeV-1 isolates (Figure 2). A similar pattern was found in
a VP1-based phylogenetic study of Dutch strains in which
all HPeV-1 isolates formed a cluster that was distinct from
that of the Harris reference strain (13). Thus, most recent
European, Japanese, and Canadian HPeV-1 isolates appear
to be, to a certain extent, genetically distinct from the only
known HPeV-1 reference strain. Designs of molecular or
serologic diagnostic tools should take this fact into consid-
eration. Our molecular characterization also enabled us to
detect and differentiate the 2 known HPeV-2 lineages with
1 isolate close to the Williamson reference strain and the
other 2 isolates being more related to the Connecticut
strain. On the other hand, our HPeV-3 were found to be
rather genetically homogeneous and constituted a unique
cluster, which also included the Japanese HPeV-3 strains.
Since HPeVs are considered important nosocomial agents,
differentiating viral strains for epidemiologic purposes
may be relevant. Our molecular approach demonstrated
the link between 2 HPeV-2 isolates recovered from twins
(100% nt identity) and showed that all other HPeV-1
and -3 isolates were unrelated. 
The HPeV-1 serotype was shown to be the most fre-
quent, representing >70% of our HPeV isolates. The
HPeV-2 serotype was the less frequent, with only 3 cases
reported. A very limited number of HPeV-2 infections has
also been reported by a Swedish group (8). In addition, in
a recent Dutch study that reported 37 HPeV isolates recov-
ered during the 2000–2005 period, no HPeV-2 isolates
were recovered compared to 27 HPeV-1 and 10 HPeV-3
(13). The recently described HPeV-3 serotype, although
less frequent than HPeV-1, appears to be more frequent
than HPeV-2, both in our study and in the Dutch study
(13).
HPeVs have been generally isolated from stool and
NPA (6–8). Accordingly, our isolates were predominantly
isolated from NPA (57%) and stool (25%) specimens;
however, some isolates were also recovered from other
types of samples, including throat swabs, endotracheal
secretions, CSF, and urine, highlighting the need to collect
multiple specimens for optimal detection of these viruses.
With the exception of one 78-year-old case-patient, all
HPeV infections described in this retrospective study were
in children <4 years, which confirms the particular impor-
tance of these pathogens in the pediatric population (3).
However, only prospective evaluation will determine the
true incidence of HPeV infections in both the pediatric and
adult populations. Interestingly, all of our HPeV-3 cases
involved neonates with a mean age of 0.7 month, whereas
HPeV-1 infections occurred in significantly older children
whose mean age was 14.6 months. A similar finding was
reported in Dutch patients (13), and this situation could be
related to the presence of variable proportions of maternal
antibodies against these different viruses.
Our study showed that HPeVs seem to share with
HEVs the same epidemiologic pattern, i.e., a peak during
the summer-fall months. In addition, the epidemiology of
HPeV-3 appears to be similar to that of the 2 other HPeV
types in our study, whereas it was slightly different in the
Dutch study (13). A better knowledge of the epidemiology
of these viruses may have important consequences for
diagnostic laboratories. A multiplex RT-PCR that allows
the simultaneous detection of HEVs and HPeVs could be
particularly useful during the summer-fall seasons if the
epidemiologic pattern seen in our study is confirmed by
others.
Most HPeV cases reported here were associated with
hospitalizations (mean hospital stay 3.7 days). No differ-
ences were found between the 3 HPeV types in this aspect.
Nevertheless, only HPeV-1 infections led to severe dis-
eases, i.e., 3 patients were transferred to an intensive care
unit. Our study also showed the high rate of underlying
diseases in our infected patients, which were particularly
frequent (≈50%) in HPeV-1 cases. Also, substantial differ-
ences in clinical signs and symptoms were seen between
the HPeV types. All 7 patients with HPeV-2 and -3 infec-
tions were admitted with a diagnosis of sepsislike illness in
contrast to none of the 20 HPeV-1 patients (p = 0.001).
Sepsislike illness seems to be a notable clinical feature of
HPeV-3 infection, as first reported by us (11) and recently
by a Dutch group (13). This clinical variation may be
explained by the younger age of HPeV-2– and -3–infected
children.
HPeV-1 has been reported to cause mainly gastroin-
testinal and respiratory diseases and fewer CNS symptoms
(3,8,9,13). Accordingly, bronchiolitis, pneumonitis, acute
otitis media, and enteritis were frequently diagnosed in
HPeV-1–infected children in our study, whereas this HPeV
type was not involved in CNS infections. Of interest, bron-
chiolitis was seen only in HPeV-1–infected children,
representing almost 50% of the cases. However, in 4 of
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found as copathogen; thus, the relative contribution of
HPeV-1 in cases of bronchiolitis needs to be further stud-
ied. Our study also suggested that HPeV-1 could be
involved in severe infections, as shown by 2 cases of bilat-
eral pneumonia, leading to death in a 4-year-old boy with
ALL and in a 78-year-old woman. Since no autopsy was
performed, the role of HPeV-1 in these fatal cases cannot
be confirmed, although no other microorganisms could be
recovered premortem.
In conclusion, this study confirms that all 3 HPeVs are
pathogens that are particularly important in the pediatric
setting, that is, responsible for hospitalizations and some
severe infections. HPeV infections could encompass a
variety of clinical syndromes with respiratory, gastroin-
testinal, cerebral, and sepsislike diseases. Molecular assays
now allow for their specific detection and should con-
tribute to increased knowledge regarding their incidence,
epidemiologic features, and clinical manifestations.
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